<DOC>
	<DOCNO>NCT02062255</DOCNO>
	<brief_summary>Obesity promote bad outcome post-menopausal breast cancer patient .</brief_summary>
	<brief_title>Impact COX2 Sera Biomarkers From Obese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Aspirin</mesh_term>
	<criteria>At least 18 year age Postmenopausal confirm medical history Ability understand purpose risk study sign write informed consent form approve investigator 's IRB/Ethics Committee Evidence active cancer ( patient prior history malignancy encourage participate , due cytokine level associate malignancy must evidence disease ) Cachexia Active systemic illness ( infection include viral illness Hepatitis HIV ) Chronic use aspirin omega3 free fatty acid supplementation within last 60 day ( defined great equal 7 consecutive day ) Known hypersensitivity aspirin and/or omega3 fatty acid Actively receive physiciandirected regimen aspirin and/or receive herapeutic/prophylactic anticoagulation Any aspirin omega3 free fatty acid supplementation within last 14 day Subjects pregnant History medical noncompliance</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Asprin</keyword>
	<keyword>Omega-3 Free Fatty Acids</keyword>
	<keyword>Obesity</keyword>
	<keyword>COX-2 inhibitor</keyword>
</DOC>